Chart, page-5428

Agreed.
The CR bought in funds at greater than the previous 12 month Vwap. The blip above 26c lasted 4 days. EMA news, without any guidance on how it would be funded, would have also lead to a share price fizzle. A CR announcement and trial funding plan at the same time was appropriate. Retail investors not participating in the CR sabotaged their own investment, and some of those now whine of where trial funds will come from. But the proportion of the CR allocated to retail investors was too large. But this is the past, and cant be changed.

Unfortunate timing for the CR as the worlds markets started to tumble at the same time.

ANP is at the high risk end of the market. Potentially 1 trial away from progressing into revenue production. ATL1102 is being set up to become a platform drug. So risk is still high, but potential for reward keeps growing.